Trial reportThe Journal of infectious diseases2010
The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection.
Trial report in The Journal of infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Adjunct Therapy for CD4Frontiers in immunology · 2021Pooled it
- Review
- Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?Frontiers in medicine · 2021Review
- Review
- Pediatric HIV: the Potential of Immune Therapeutics to Achieve Viral Remission and Functional Cure.Current HIV/AIDS reports · 2020Review
- Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.AIDS research and human retroviruses · 2019Review
- Inhibition of p38 MAPK in combination with ART reduces SIV-induced immune activation and provides additional protection from immune system deterioration.PLoS pathogens · 2018Article
- Review
- Residual inflammation and viral reservoirs: alliance against an HIV cure.Current opinion in HIV and AIDS · 2016Review
- Targeting the latent reservoir to achieve functional HIV cure.F1000Research · 2016Review
- HIV-1 gag: an emerging target for antiretroviral therapy.Current topics in microbiology and immunology · 2015Review
- HIV integrase and the swan song of the CD4 T cells?Retrovirology · 2013Article
- Immune activation and collateral damage in AIDS pathogenesis.Frontiers in immunology · 2013Review
- HIV-associated chronic immune activation.Immunological reviews · 2013Review
- Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy.Critical reviews in immunology · 2013Review
- Should we treat acute HIV infection?Current HIV/AIDS reports · 2012Review
- Identifying the early post-HIV antibody seroconversion period.The Journal of infectious diseases · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Acute human immunodeficiency virus type 1 (HIV-1) infection is characterized by high levels of immune activation. Immunomodulation with cyclosporine combined with antiretroviral therapy (ART) in the setting of acute and early HIV-1 infection has been reported to result in enhanced immune reconstitution. Fifty-four individuals with acute and early infection were randomized to receive ART with 4 weeks of cyclosporine versus ART alone. In 48 subjects who completed the study, there were no significant differences between treatment arms in levels of proviral DNA or CD4(+) T cell counts. Adjunctive therapy with cyclosporine in this setting does not provide apparent virologic or immunologic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.